CPAICounterpoint Quantitative Equity ETF
Seeks long-term capital appreciation.
By Counterpoint Funds · Launched 2023
Annual Cost
0.75%
#4,069 of 6,040 · expensive
Fund Size
$437M
#1,768 of 6,040 · large
Return (1Y)
+39.1%
Track Record
2 years
#3,237 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$13,881+38.8%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundHoldings
By weightConcentration
Top 10 holdings = 20.2% of funddiversified
Adaptive Biotechnologies Corp
2.0%
Vertex Inc
2.0%
Lightpath Technologies Inc.
2.0%
Viavi Solutions Inc
2.0%
EZCORP Inc.
2.0%
The Realreal Inc
2.0%
Marqeta Inc
2.0%
United Natural Foods, Inc.
2.0%
International Business Machines Corp.
2.0%
Star Bulk Carriers Corp.
2.0%
Asset allocation
Stocks
99.8%
Cash
0.2%
By sector
Technology
32.5%
Healthcare
28.7%
Energy
14.8%
Industrials
6.9%
Basic Materials
3.9%
Consumer Cyclical
3.7%
Communication
3.6%
Consumer Defensive
3.4%
Other
2.4%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
20.5%High
Year-on-year price swings
Max drawdown
-21.5%Moderate
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- New York Stock Exchange
Full fund details
- Objective
- Seeks long-term capital appreciation.
- Strategy
- Actively manages a portfolio using a quantitative, model-based approach to select common stocks and ADRs of U.S. domiciled companies across any market capitalization. The strategy focuses on stocks ranked by the Counterpoint Machine Learning Model, which incorporates themes of value, momentum, and profitability, with sector exposure limited to 35% and industry exposure to 25%.
- Inception date
- November 28, 2023
- Fund family
- Counterpoint Funds
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save CPAI to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18